Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth Baum

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Treatment Options in Cardiovascular Medicine|June 23, 2017
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical DataAshwin Durairaj, Alberto Sabates, Jonathan Nieves, et al.
JACC. Case Reports|November 21, 2025
Lipoprotein X: A Cause for Misleading Levels of Low-Density LipoproteinRomeena Lee, Seth Baum, Torfay Roman, et al.
Future Cardiology|September 22, 2020
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reductionWilliam E Boden, Seth Baum, Peter P Toth, et al.
Clinical Cardiology|September 5, 2015
Insights Into Statin IntoleranceStephen Kopecky, Seth Baum, JoAnne M Foody, et al.
Journal of General Internal Medicine|July 25, 2025
Physician Perceptions, Knowledge, and Implementation of Lipid-Lowering Guidelines in the USATaruja Karmarkar, Lori D Bash, Jason Exter, et al.
Journal of the American Heart Association|March 15, 2021
Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-AnalysisSiva H Yedlapati, Safi U Khan, Swapna Talluri, et al.
Journal of Clinical Lipidology|October 16, 2018
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH studyDirk J Blom, Louis O'Dea, Andres Digenio, et al.
Lancet (London, England)|November 16, 2019
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mustafa R Bashir, Cynthia D Guy, et al.
Circulation|July 7, 2025
Correction to: Evinacumab for Pediatric Patients With Homozygous Familial HypercholesterolemiaAlbert Wiegman, Susanne Greber-Platzer, Shazia Ali, et al.
Circulation|October 20, 2023
Evinacumab for Pediatric Patients With Homozygous Familial HypercholesterolemiaAlbert Wiegman, Susanne Greber-Platzer, Shazia Ali, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Treatment Options in Cardiovascular Medicine|June 23, 2017
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical DataAshwin Durairaj, Alberto Sabates, Jonathan Nieves, et al.
JACC. Case Reports|November 21, 2025
Lipoprotein X: A Cause for Misleading Levels of Low-Density LipoproteinRomeena Lee, Seth Baum, Torfay Roman, et al.
Future Cardiology|September 22, 2020
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reductionWilliam E Boden, Seth Baum, Peter P Toth, et al.
Clinical Cardiology|September 5, 2015
Insights Into Statin IntoleranceStephen Kopecky, Seth Baum, JoAnne M Foody, et al.
Journal of General Internal Medicine|July 25, 2025
Physician Perceptions, Knowledge, and Implementation of Lipid-Lowering Guidelines in the USATaruja Karmarkar, Lori D Bash, Jason Exter, et al.
Journal of the American Heart Association|March 15, 2021
Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-AnalysisSiva H Yedlapati, Safi U Khan, Swapna Talluri, et al.
Journal of Clinical Lipidology|October 16, 2018
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH studyDirk J Blom, Louis O'Dea, Andres Digenio, et al.
Lancet (London, England)|November 16, 2019
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mustafa R Bashir, Cynthia D Guy, et al.
Circulation|July 7, 2025
Correction to: Evinacumab for Pediatric Patients With Homozygous Familial HypercholesterolemiaAlbert Wiegman, Susanne Greber-Platzer, Shazia Ali, et al.
Circulation|October 20, 2023
Evinacumab for Pediatric Patients With Homozygous Familial HypercholesterolemiaAlbert Wiegman, Susanne Greber-Platzer, Shazia Ali, et al.
Pageof 1